Chemical reversal of the RNA gain of function in myotonic dystrophy.
作者信息
Cooper Thomas A
机构信息
Department of Pathology and Molecular, Baylor College of Medicine, Houston, TX 77030, USA.
出版信息
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18433-4. doi: 10.1073/pnas.0910643106. Epub 2009 Oct 28.
Abstract
摘要
相似文献
1
Chemical reversal of the RNA gain of function in myotonic dystrophy.
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18433-4. doi: 10.1073/pnas.0910643106. Epub 2009 Oct 28.
2
Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18551-6. doi: 10.1073/pnas.0903234106. Epub 2009 Oct 12.
3
Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Nucleic Acid Ther. 2020 Apr;30(2):80-93. doi: 10.1089/nat.2019.0811. Epub 2019 Dec 23.
4
Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Biochimie. 2011 Nov;93(11):2006-12. doi: 10.1016/j.biochi.2011.06.028. Epub 2011 Jul 13.
5
A reversal of misfortune for myotonic dystrophy?
N Engl J Med. 2006 Oct 26;355(17):1825-7. doi: 10.1056/NEJMcibr064708.
6
In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
PLoS One. 2017 Jun 5;12(6):e0178931. doi: 10.1371/journal.pone.0178931. eCollection 2017.
7
Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
J Biol Chem. 2016 Aug 12;291(33):17165-77. doi: 10.1074/jbc.M115.710616. Epub 2016 Jun 13.
8
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.
Mol Cell. 2002 Jul;10(1):35-44. doi: 10.1016/s1097-2765(02)00563-4.
9
A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Hum Mol Genet. 2017 Aug 15;26(16):3056-3068. doi: 10.1093/hmg/ddx190.
10
Molecular biology. Neutralizing toxic RNA.
Science. 2009 Jul 17;325(5938):272-3. doi: 10.1126/science.1177452.
引用本文的文献
1
Dysregulation of mRNA Localization and Translation in Genetic Disease.
J Neurosci. 2016 Nov 9;36(45):11418-11426. doi: 10.1523/JNEUROSCI.2352-16.2016.
2
Altered Ca2+ homeostasis and endoplasmic reticulum stress in myotonic dystrophy type 1 muscle cells.
Genes (Basel). 2013 Jun 4;4(2):275-92. doi: 10.3390/genes4020275.
3
Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.
J Med Chem. 2013 Dec 12;56(23):9471-9481. doi: 10.1021/jm400794z. Epub 2013 Nov 21.
4
SMMRNA: a database of small molecule modulators of RNA.
Nucleic Acids Res. 2014 Jan;42(Database issue):D132-41. doi: 10.1093/nar/gkt976. Epub 2013 Oct 24.
5
Targeting RNA to treat neuromuscular disease.
Nat Rev Drug Discov. 2011 Aug 1;10(8):621-37. doi: 10.1038/nrd3459.
6
Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates.
Behav Brain Funct. 2010 May 19;6:25. doi: 10.1186/1744-9081-6-25.
本文引用的文献
1
PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.
J Clin Invest. 2009 Dec;119(12):3797-806. doi: 10.1172/JCI37976. Epub 2009 Nov 9.
2
Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18551-6. doi: 10.1073/pnas.0903234106. Epub 2009 Oct 12.
3
A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding.
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16068-73. doi: 10.1073/pnas.0901824106. Epub 2009 Sep 8.
4
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13915-20. doi: 10.1073/pnas.0905780106. Epub 2009 Aug 10.
5
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.
Science. 2009 Jul 17;325(5938):336-9. doi: 10.1126/science.1173110.
6
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.
J Am Chem Soc. 2009 Jul 22;131(28):9767-79. doi: 10.1021/ja9020149.
7
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2.
ACS Chem Biol. 2009 May 15;4(5):345-55. doi: 10.1021/cb900025w.
8
RNA and disease.
Cell. 2009 Feb 20;136(4):777-93. doi: 10.1016/j.cell.2009.02.011.
9
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1).
J Am Chem Soc. 2008 Dec 3;130(48):16254-61. doi: 10.1021/ja804398y.
10
Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
Mol Cell. 2007 Oct 12;28(1):68-78. doi: 10.1016/j.molcel.2007.07.027.
Zotero 插件